科学家着手梳理长新冠的相关问题。
Scientists set out to connect the dots on long COVID.
机构信息
Nature Methods, .
出版信息
Nat Methods. 2021 May;18(5):449-453. doi: 10.1038/s41592-021-01145-z.
Abstract
With grit, urgency and creativity, scientists address the puzzle of long-haul COVID.
摘要
科学家们以坚韧、紧迫感和创造力，解决长新冠之谜。
相似文献
1
Scientists set out to connect the dots on long COVID.
Nat Methods. 2021 May;18(5):449-453. doi: 10.1038/s41592-021-01145-z.
2
Antibody Response to SARS-CoV-2 is Associated with Long-term Clinical Outcome in Patients with COVID-19: a Longitudinal Study.
J Clin Immunol. 2021 Oct;41(7):1490-1501. doi: 10.1007/s10875-021-01083-7. Epub 2021 Jul 17.
3
Vaccines may cause rare, Long Covid-like symptoms.
Science. 2022 Jan 28;375(6579):364-366. doi: 10.1126/science.ada0536. Epub 2022 Jan 27.
4
Long-term SARS-CoV-2-specific immune and inflammatory responses in individuals recovering from COVID-19 with and without post-acute symptoms.
Cell Rep. 2021 Aug 10;36(6):109518. doi: 10.1016/j.celrep.2021.109518. Epub 2021 Aug 6.
5
Rogue antibodies could be driving severe COVID-19.
Nature. 2021 Feb;590(7844):29-31. doi: 10.1038/d41586-021-00149-1.
6
Mild and Asymptomatic COVID-19 Convalescents Present Long-Term Endotype of Immunosuppression Associated With Neutrophil Subsets Possessing Regulatory Functions.
Front Immunol. 2021 Sep 29;12:748097. doi: 10.3389/fimmu.2021.748097. eCollection 2021.
7
Dynamic Changes of the Blood Chemistry in Syrian Hamsters Post-Acute COVID-19.
Microbiol Spectr. 2022 Feb 23;10(1):e0236221. doi: 10.1128/spectrum.02362-21.
8
Early and High SARS-CoV-2 Neutralizing Antibodies Are Associated with Severity in COVID-19 Patients from India.
Am J Trop Med Hyg. 2021 Jun 17;105(2):401-406. doi: 10.4269/ajtmh.21-0014.
9
The Post-Acute Phase of SARS-CoV-2 Infection in Two Macaque Species Is Associated with Signs of Ongoing Virus Replication and Pathology in Pulmonary and Extrapulmonary Tissues.
Viruses. 2021 Aug 23;13(8):1673. doi: 10.3390/v13081673.
10
Sex-based differences in severity and mortality in COVID-19.
Rev Med Virol. 2021 Nov;31(6):e2223. doi: 10.1002/rmv.2223. Epub 2021 Mar 1.
引用本文的文献
1
Understanding autoimmune response after SARS-CoV-2 infection and the pathogenesis/mechanisms of long COVID.
Med Rev (2021). 2024 May 27;4(5):367-383. doi: 10.1515/mr-2024-0013. eCollection 2024 Oct.
2
Association of COVID-19 with acute and post-acute risk of multiple different complications and mortality in patients infected with omicron variant stratified by initial disease severity: a cohort study in Hong Kong.
BMC Med. 2024 Oct 14;22(1):461. doi: 10.1186/s12916-024-03630-6.
3
Prevalence of persistent SARS-CoV-2 in a large community surveillance study.
Nature. 2024 Feb;626(8001):1094-1101. doi: 10.1038/s41586-024-07029-4. Epub 2024 Feb 21.
4
Confirmation of COVID-19 infection status and reporting of Long COVID symptoms in a population-based birth cohort: No evidence of a nocebo effect.
J Health Psychol. 2024 May;29(6):581-594. doi: 10.1177/13591053241228711. Epub 2024 Jan 25.
5
Emerging Landscape of Preclinical Models for Studying COVID-19 Neurologic Diseases.
ACS Pharmacol Transl Sci. 2023 Sep 6;6(10):1323-1339. doi: 10.1021/acsptsci.3c00127. eCollection 2023 Oct 13.
6
[S1 guidelines for the management of postviral conditions using the example of post-COVID-19].
Wien Klin Wochenschr. 2023 Jul;135(Suppl 4):525-598. doi: 10.1007/s00508-023-02242-z. Epub 2023 Aug 9.
7
Microfluidic Organ-Chips and Stem Cell Models in the Fight Against COVID-19.
Circ Res. 2023 May 12;132(10):1405-1424. doi: 10.1161/CIRCRESAHA.122.321877. Epub 2023 May 11.
8
Real-world effectiveness of COVID-19 vaccines and anti-SARS-CoV-2 monoclonal antibodies against postacute sequelae of SARS-CoV-2: analysis of a COVID-19 observational registry for a diverse US metropolitan population.
BMJ Open. 2023 Apr 5;13(4):e067611. doi: 10.1136/bmjopen-2022-067611.
9
Role of the MicroRNAs in the Pathogenic Mechanism of Painful Symptoms in Long COVID: Systematic Review.
Int J Mol Sci. 2023 Feb 10;24(4):3574. doi: 10.3390/ijms24043574.
10
[Genomics in Public Health Scientific evidence and prospects for integration in the prevention practice].
J Prev Med Hyg. 2023 Jan 13;63(3 Suppl 2):E1-E29. doi: 10.15167/2421-4248/jpmh2022.63.3s2. eCollection 2023 Mar.
本文引用的文献
1
The first 12 months of COVID-19: a timeline of immunological insights.
Nat Rev Immunol. 2021 Apr;21(4):245-256. doi: 10.1038/s41577-021-00522-1. Epub 2021 Mar 15.
2
Evolution of antibody immunity to SARS-CoV-2.
Nature. 2021 Mar;591(7851):639-644. doi: 10.1038/s41586-021-03207-w. Epub 2021 Jan 18.
3
Autoantibodies against type I IFNs in patients with life-threatening COVID-19.
Science. 2020 Oct 23;370(6515). doi: 10.1126/science.abd4585. Epub 2020 Sep 24.
4
Inborn errors of type I IFN immunity in patients with life-threatening COVID-19.
Science. 2020 Oct 23;370(6515). doi: 10.1126/science.abd4570. Epub 2020 Sep 24.
5
Systems-Level Immunomonitoring from Acute to Recovery Phase of Severe COVID-19.
Cell Rep Med. 2020 Aug 25;1(5):100078. doi: 10.1016/j.xcrm.2020.100078. Epub 2020 Aug 5.
6
Chronic Dengue Virus Panencephalitis in a Patient with Progressive Dementia with Extrapyramidal Features.
Ann Neurol. 2019 Nov;86(5):695-703. doi: 10.1002/ana.25588. Epub 2019 Sep 11.
7
Severe acute respiratory syndrome coronavirus infection of mice transgenic for the human Angiotensin-converting enzyme 2 virus receptor.
J Virol. 2007 Feb;81(3):1162-73. doi: 10.1128/JVI.01702-06. Epub 2006 Nov 15.
Zotero 插件